Dihexa vs P21

Dihexa

THERE IS ESSENTIALLY NO HUMAN DATA ON DIHEXA. It is a small-molecule angiotensin IV analogue developed in an academic laboratory (Washington State University) that potentiates hepatocyte growth factor signaling at its receptor c-Met and promotes synaptogenesis. Every efficacy claim attached to it comes from rodent work: scopolamine-impaired and lesioned rats, and Parkinson and Alzheimer disease models. It has never completed a published human trial, there is no published human pharmacokinetic or toxicology data, and no approved product exists anywhere. Because of that, the range given here is deliberately narrow and conservative: it is derived from what unregulated users report taking (roughly 3-20 mg per day orally or transdermally), NOT from any dose-finding study, and it should be read as a description of practice, not a recommendation. The active-malignancy flag is not a formality: c-Met is a well-characterized oncogenic pathway and chronically potentiating it in a person with an existing or suspected cancer is a real theoretical hazard. It is taken as a powder or in a carrier rather than reconstituted for injection, so the vial and bacteriostatic water fields do not apply in the usual way.

P21

THERE IS ESSENTIALLY NO HUMAN DATA ON P21. It is a small adamantylated tetrapeptide derivative (Ac-DGGL-amide) of an 11-residue active region of ciliary neurotrophic factor, designed to be orally available and blood-brain-barrier permeable. The entire evidence base is preclinical: transgenic and aged rodent models of Alzheimer disease and Down syndrome, reporting increased neurogenesis and BDNF signaling and reduced tau hyperphosphorylation, from the group that developed it at the New York State Institute for Basic Research. No human trial has been published, no human pharmacokinetic or toxicology data exists, and no approved product exists anywhere. Rodent work dosed it orally or subcutaneously; the subcutaneous and intranasal routes listed here reflect how unregulated users actually take it. The range given is deliberately narrow and conservative and is extrapolated from that practice, NOT from any dose-finding study - treat it as a description, not a recommendation. It is frequently confused with the unrelated cell-cycle protein p21 (CDKN1A); they are not the same thing.